ArticlePregnancy (Hoboken, N.J.)2026
Xenobiotic transfer of onabotulinumtoxinA using an ex vivo human placental perfusion model: A pilot study.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: OnabotulinumtoxinA is an effective preventive therapy for chronic migraine; however, data on fetal exposure during pregnancy are limited. We aimed to evaluate transplacental transfer of onabotulinumtoxinA using an ex vivo human placental perfusion model. Study design: Five term placentas from uncomplicated singleton pregnancies were cannulated and perfused using a validated ex vivo model. OnabotulinumtoxinA (100 units in Trials 1 and 2; 200 units in Trials 3-5) was introduced into the maternal circuit with antipyrine (1 g/L) as a positive transfer control. Maternal and fetal samples were collected every 30 min for 3 h. Fetal artery pressure and pH were monitored to ensure system integrity. Antipyrine was measured using ultra-high performance liquid chromatography-mass spectrometry, and onabotulinumtoxinA using enzyme-linked immunosorbent assay. Results: OnabotulinumtoxinA was not detected in fetal samples at any time point. Antipyrine demonstrated expected transplacental transfer, confirming model validity. Maternal onabotulinumtoxinA concentrations decreased slightly over time. Conclusion: OnabotulinumtoxinA was not detected in the fetal circulation under study conditions, suggesting minimal transplacental transfer. These preliminary findings support its potential use in pregnancy; however, in vivo studies are needed to confirm maternal-fetal pharmacokinetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.